1 Apr 2019 07:00
1 April 2019
AMPHION INNOVATIONS PLC
("Amphion" or "the Company")
Update on Loan Facility
London and New York, 1 April 2019 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces that, further to the announcement of the 11 March 2019, the Company has pledged its holding of Polarean Imaging plc ("Polarean") as additional security against the loan facility (the "Facility") with the Company's debt provider ("the Lender").
The loan amount under the Facility continues to be secured by the Company's pledge of 18,000,591 ordinary shares of Motif Bio plc ("Motif"). Amphion currently holds 18,779,611 ordinary shares of Motif, representing 5.5% of the issued share capital. From 1 April 2019, the loan is also secured by the Company's holding of 18,372,523 shares of Polarean.
Currently, the loan balance under the Facility is approximately US $3.65 million (including fees and accrued interest). The loan is repayable on 30 September 2019. Amphion has transferred the legal title to, but retains the beneficial interest in, the total pledged shares in both Motif and Polarean. Following completion of a lock-in period in respect of the Polarean shares held, the Lender has agreed to adhere to the terms of an orderly market agreement for the next 12 months.
Under the amended terms of the Facility, the interest rate will remain at 10% per annum. The Lender will also receive 15% of the future appreciation on Amphion's holding of 10,000,000 ordinary shares in Motif, above 10 pence as well as participate in 15% of the appreciation in 10,000,000 ordinary shares of Polarean held by the Company, above 18 pence.
The Lender's participation in the appreciation of the Motif and Polarean shares will expire on the earlier of 30 September 2021 or when the Company has sold all of its ordinary shares in Motif and Polarean.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
For further information please contact:
Amphion Innovations | Tel: +1 (212) 210 6224 | ||||
Charlie Morgan |
| ||||
|
| ||||
Panmure Gordon Limited (Nominated Adviser and Corporate Broker) | Tel: +44 (0)20 7886 2500 | ||||
Emma Earl/ Freddy Crossley (Corporate Finance) |
| ||||
Charles Leigh-Pemberton (Corporate Broking) |
| ||||
|
| ||||
SP Angel Corporate Finance LLP (Joint Corporate Broker) | Tel: +44 (0) 20 3470 0470 | ||||
David Hignell (Corporate Finance) |
| ||||
Vadim Alexandre (Corporate Broking) |
| ||||
|
| ||||
Walbrook PR | Tel: +44 (0)20 7933 8780 or amphion@walbrookpr.com | ||||
Anna Dunphy / Paul McManus |
| ||||
|
| ||||
About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses. We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.
On the web: www.amphionplc.com